To clarify whether the effect of sh-SLC7A5 on the malignant progression of oxaliplatin-resistant GC cells was related to the inhibition of glycolysis, different doses of glutathione were used in the follow-up study. The gene discussed is SLC7A5; the disease is gastric cancer.